NuPathe (PATH) halted, news pending
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NuPathe (PATH) Announces FDA Approval of Zecuity; Shares Surge
January 17, 2013 7:33 PM ESTNuPathe Inc. (NASDAQ: PATH) ramped 18% after-hours Thursday after the company announced FDA approval of Zecuity for the acute treatment of migraine with or without aura in adults.
Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine... More
